MDT vs TNDM: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: MDT is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MDT and TNDM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MDT and TNDM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Its business spans four main areas: Cardiovascular (pacemakers, defibrillators, heart valves, and cardiac ablation), Neuroscience (spine implants, neuromodulation for pain and movement disorders, and surgical navigation), Medical Surgical (surgical stapling, energy devices, and a growing robotic-surgery platform), and Diabetes (insulin pumps and continuous glucose monitoring). The company sells primarily to hospitals, surgeons, and health systems, generating durable, recurring demand tied to procedure volumes and chronic-disease management. Medtronic's scale gives it deep relationships with providers, a large installed base of devices, and the resources to fund extensive R&D and acquisitions. Growth depends on new product cycles, pipeline approvals, and global expansion, especially in emerging markets. Founded in 1949 and headquartered in Ireland for tax purposes (operationally rooted in Minnesota), Medtronic is a large-cap, dividend-growing medical-technology company tied to long-term healthcare demand and aging demographics.

Full MDT guide

Tandem Diabetes Care designs, makes, and sells insulin pumps for people with diabetes. Its flagship products are the t:slim X2 pump and the much smaller Tandem Mobi system, both running Control-IQ+ automated insulin delivery software that reads data from a continuous glucose monitor (CGM) and automatically adjusts insulin dosing. The business works on a razor-and-blade model: Tandem earns an up-front sale when a customer adopts a pump, then recurring revenue from the disposable cartridges, infusion sets, and other supplies that customer buys for years afterward. Pumps integrate with third-party CGMs from Dexcom (G6/G7) and Abbott (FreeStyle Libre), which Tandem does not make itself.

Full TNDM guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MDT drivers: Diversified device portfolio; Innovation pipeline and new product cycles.
• TNDM drivers: Recurring supplies and a growing installed base; Tandem Mobi and Control-IQ+ product cycle.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. For TNDM, competition is the central risk: Insulet's tubeless Omnipod 5 is the fastest-growing system in the market, Medtronic remains a large incumbent, and newer entrants like Beta Bionics' iLet and Sequel's twiist add pressure, all of which can squeeze Tandem's pricing and pump share.

Pick MDT if you believe its drivers more; TNDM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MDT and TNDM guides.

MDT. Medtronic trades at a moderate valuation relative to faster-growing medtech peers, reflecting its scale, diversification, and reliable dividend but also a track record of slower organic growth. The multiple has expanded when new product cycles reaccelerated growth and compressed during periods of execution stumbles. The yield gives it a defensive, income-oriented profile within healthcare.

TNDM. Tandem is best read as a growth medtech rather than a mature, profitable company. The model is razor-and-blade: pumps are sold (sometimes at thin margin) to build an installed base, and the recurring supplies that base buys over the following years drive higher-margin revenue. Heavy spending on research, sales, and manufacturing scale is why the company has not been consistently profitable on a GAAP basis even at roughly $1 billion in sales, so investors tend to watch pump shipments, installed-base growth, gross margin, and the path to positive adjusted EBITDA rather than a simple P/E ratio.

Headline figures (approximate, early 2026): MDT shows revenue (ttm) ~$33 billion, operating margin ~20% (non-GAAP higher; GAAP affected by amortization), net income (ttm) ~$4.5 billion, eps (ttm) ~$3.50 GAAP; non-GAAP higher; TNDM shows fy2025 revenue ~$1.0 billion worldwide, pump shipments International >40,000 for FY2025; ~29,000 worldwide in Q1 2026, u.s. installed base ~324,000 customers (12/31/25), gross margin (non-gaap) ~54% FY2025; ~58% Q4 2025.

MDT and TNDM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MDT and TNDM exposure against your real portfolio. It is not an investment adviser.